Cullinan Therapeutics (CGEM) News Today $12.02 0.00 (0.00%) (As of 12:40 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Geode Capital Management LLC Buys 231,935 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Geode Capital Management LLC increased its position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 23.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,208,421 shares of the companDecember 29 at 3:17 AM | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) CEO Nadim Ahmed Sells 8,400 SharesDecember 28 at 6:36 AM | americanbankingnews.comNadim Ahmed Sells 8,400 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) StockDecember 28 at 6:04 AM | insidertrades.comCullinan Therapeutics (NASDAQ:CGEM) Shares Down 2.9% - Here's WhyDecember 28 at 6:02 AM | americanbankingnews.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) CEO Sells $99,708.00 in StockCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) CEO Nadim Ahmed sold 8,400 shares of the stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $11.87, for a total value of $99,708.00. Following the transaction, the chief executive officer now owns 263,150 shares of the company's stock, valued at $3,123,590.50. The trade was a 3.09 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.December 27 at 7:39 PM | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Trading Down 2.9% - Should You Sell?Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 2.9% - Time to Sell?December 26, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives $31.67 Consensus Price Target from BrokeragesDecember 26, 2024 | americanbankingnews.comBarclays PLC Acquires 51,300 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Barclays PLC lifted its holdings in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 26.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 248,614 shares of the companDecember 23, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Recommendation of "Buy" by AnalystsCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) has been given a consensus rating of "Buy" by the seven research firms that are currently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month target priceDecember 23, 2024 | marketbeat.comCullinan Therapeutics chief scientific officer sells $53,547 in stockDecember 23, 2024 | investing.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by State Street CorpState Street Corp boosted its position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 20.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,337,222 shares of the company's stock aDecember 21, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells $53,547.13 in StockCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 4,693 shares of Cullinan Therapeutics stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $11.41, for a total transaction of $53,547.13. Following the completion of the transaction, the insider now directly owns 99,760 shares in the company, valued at $1,138,261.60. This represents a 4.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.December 20, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 5.6% - What's Next?Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 5.6% - Here's What HappenedDecember 20, 2024 | marketbeat.comFranklin Resources Inc. Has $35.56 Million Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Franklin Resources Inc. decreased its position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 10.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,191,262 shares of the company's stoDecember 19, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Trading Down 4% - Here's WhyCullinan Therapeutics (NASDAQ:CGEM) Shares Down 4% - Here's What HappenedDecember 18, 2024 | marketbeat.comJennifer Michaelson Sells 3,489 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) StockDecember 17, 2024 | insidertrades.comInsider Selling: Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells 3,489 Shares of StockCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 3,489 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $12.52, for a total transaction of $43,682.28. Following the transaction, the insider now directly owns 104,453 shares in the company, valued at $1,307,751.56. The trade was a 3.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.December 16, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Increase in Short InterestCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) was the recipient of a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 9,160,000 shares, a growth of 5.2% from the November 15th total of 8,710,000 shares. Approximately 24.7% of the company's shares are short sold. Based on an average daily volume of 544,700 shares, the short-interest ratio is currently 16.8 days.December 16, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Position Raised by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. boosted its holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 14.4% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 423,959 shares of the company's stoDecember 12, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Stock, Short Interest ReportDecember 11, 2024 | benzinga.comCullinan Therapeutics Inc CGEMDecember 5, 2024 | morningstar.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by RTW Investments LPRTW Investments LP lifted its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 62.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,705,960 shares of the company's stock afterDecember 5, 2024 | marketbeat.comPatient Square Capital LP Buys Shares of 824,705 Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Patient Square Capital LP bought a new stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 824,705 shares of the comDecember 4, 2024 | marketbeat.comHolocene Advisors LP Raises Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Holocene Advisors LP lifted its position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 16.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,533,579 shares of the company's stock after purchasing an additional 217,574 shares during tDecember 3, 2024 | marketbeat.comWalleye Capital LLC Has $5.50 Million Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Walleye Capital LLC increased its position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 253.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 328,417 shares of the company's stDecember 2, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by Braidwell LPBraidwell LP increased its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 567.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,176,173 shares of the company's stock after purchasiNovember 29, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Buy" from BrokeragesCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) has received an average rating of "Buy" from the seven ratings firms that are presently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 12-month price objective aNovember 28, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Recommendation of "Buy" by BrokeragesShares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) have earned an average recommendation of "Buy" from the seven ratings firms that are presently covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1November 28, 2024 | marketbeat.comCullinan Therapeutics Announces Q3 2024 Progress and OutlookNovember 21, 2024 | markets.businessinsider.comWhat is Leerink Partnrs' Forecast for CGEM FY2025 Earnings?Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Equities researchers at Leerink Partnrs lifted their FY2025 earnings estimates for Cullinan Therapeutics in a research note issued to investors on Monday, November 18th. Leerink Partnrs analyst A. Berens now expects that the company will pNovember 20, 2024 | marketbeat.comCullinan Therapeutics: Promising Developments and Strategic Growth in Autoimmune TherapiesNovember 20, 2024 | markets.businessinsider.comCullinan Management (CGEM) Has a New Rating from WedbushNovember 20, 2024 | markets.businessinsider.comCullinan Therapeutics (NASDAQ:CGEM) Shares Down 6.3% - Time to Sell?Cullinan Therapeutics (NASDAQ:CGEM) Trading Down 6.3% - Here's What HappenedNovember 15, 2024 | marketbeat.comCullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024November 14, 2024 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Intellia Therapeutics (NTLA)November 11, 2024 | markets.businessinsider.comInsider Selling: Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells 8,000 Shares of StockNovember 8, 2024 | insidertrades.comCullinan Therapeutics sees cash runway into 2028November 7, 2024 | markets.businessinsider.comCullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | finance.yahoo.comCullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare ConferenceNovember 5, 2024 | globenewswire.comCullinan Therapeutics to present preclinical data for CLN-978November 4, 2024 | markets.businessinsider.comCullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024November 4, 2024 | globenewswire.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Buy" by BrokeragesShares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) have been given a consensus rating of "Buy" by the seven brokerages that are currently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 12 month targNovember 3, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Stock, Option ChainNovember 1, 2024 | benzinga.comCullinan Therapeutics (NASDAQ:CGEM) Stock Quotes, Forecast and News SummaryNovember 1, 2024 | benzinga.comWhat is Leerink Partnrs' Estimate for CGEM FY2027 Earnings?Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Analysts at Leerink Partnrs issued their FY2027 EPS estimates for shares of Cullinan Therapeutics in a report released on Monday, October 28th. Leerink Partnrs analyst A. Berens expects that the company will post earnings of $0.54 per sharOctober 30, 2024 | marketbeat.comUBS Initiates Coverage of Cullinan Therapeutics (CGEM) with Buy RecommendationOctober 25, 2024 | msn.comCullinan Therapeutics initiated with a Buy at UBSOctober 24, 2024 | markets.businessinsider.comCullinan Therapeutics (NASDAQ:CGEM) Receives New Coverage from Analysts at UBS GroupUBS Group assumed coverage on shares of Cullinan Therapeutics in a research report on Thursday. They issued a "buy" rating and a $30.00 price objective for the company.October 24, 2024 | marketbeat.comSG Americas Securities LLC Sells 70,115 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)SG Americas Securities LLC reduced its position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 82.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,057 shares of the cOctober 22, 2024 | marketbeat.comCGEM Cullinan Therapeutics, Inc.October 19, 2024 | seekingalpha.com Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address Will the Nasdaq 100 crash? (Ad)In a world where some top money managers say you should “diversify” with a basket of stocks to help lower risk in your portfolio… And others say you should focus on only one ticker at a time because you can’t really keep detailed tabs on 10, 20 or more stocks at once… My #1 strategy to play the Nasdaq bull run has shown the power to provide the best of BOTH worlds at the same time. Because it harnesses ONE ticker that bottles up all the firepower of Apple, Nvidia, Tesla and more into one place… While I cannot promise future returns or against losses… This strategy targets major payouts OVERNIGHT! Click here to get the details. CGEM Media Mentions By Week CGEM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGEM News Sentiment▼0.680.59▲Average Medical News Sentiment CGEM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGEM Articles This Week▼103▲CGEM Articles Average Week Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SWTX News BHC News VERA News KYMR News CPRX News HCM News ARWR News DYN News AMRX News PTGX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGEM) was last updated on 12/30/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Elon Spotted at Weird Facility in Memphis? What Elon Musk is planning at a remote facility in Memphis may be his greatest achievement to date. Because...Paradigm Press | SponsoredLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredViral Trump video releasedPorter Stansberry’s latest video is going viral… In this bombshell exposé, famed economist Porter Stansberr...Porter & Company | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
